Customize your JAMA Network experience by selecting one or more topics from the list below.
2 tables omitted
Age-adjusted mortality rates for coronary heart disease (CHD) have declined steadily in the United States since the 1960s.1 Multiple factors likely have contributed to this decline in CHD deaths, including greater control of risk factors, resulting in declining incidence of CHD, and improved treatment.2 Greater control of risk factors and declining incidence can reduce CHD prevalence, whereas improved treatment that results in lower mortality rates and more persons living with CHD can increase prevalence. To estimate state-specific CHD prevalence and recent trends by age, sex, race/ethnicity, and education, CDC analyzed data from Behavioral Risk Factor Surveillance System (BRFSS) surveys for the period 2006-2010. This report summarizes the results of that analysis, which determined that, although self-reported CHD prevalence declined overall, substantial differences in prevalence existed by age, sex, race/ethnicity, education, and state of residence. These data can enable state and national health agencies to monitor CHD prevalence as a measure of progress toward meeting the Healthy People 2020 objective to reduce the U.S. rate of CHD deaths 20% from the 2007 baseline.3
BRFSS is a state-based, random-digit —dialed telephone survey of the U.S. civilian, noninstitutionalized population aged ≥18 years.4 The survey is administered in all 50 states, the District of Columbia (DC), and the U.S. territories of Guam, Puerto Rico, and the U.S. Virgin Islands. Since 2005, BRFSS has included two questions related to coronary heart disease: “Has a doctor, nurse, or other health professional ever told you that you had angina or coronary heart disease?” and “Has a doctor, nurse, or other health professional ever told you that you had a heart attack, also called a myocardial infarction?” Participants who answered “yes” to either of the questions were defined as having self-reported CHD. Those who answered “no” to both questions were defined as not having CHD. Those who answered “don't know,” refused to answer the questions, or for whom responses were missing were excluded.
CHD prevalence data were analyzed by age group, sex, education, state, and racial/ethnic population (Hispanic, white, black, Asian or Native Hawaiian/Other Pacific Islander, or American Indian/Alaska Native).* All estimates were weighted to the state population, and analyses were conducted using statistical software to account for the complex sampling design. Age-adjusted prevalence of CHD, standardized to the 2000 U.S. standard population, was estimated for each year during the period 2006-2010. Orthogonal polynomial coefficients, which were calculated recursively, were used to determine the significance of linear trends. The number of BRFSS respondents ranged from 347,790 in 2006 to 444,927 in 2010 for all states. Sample sizes for states (including DC) ranged from 1,964 in Alaska in 2010 to 39,549 in Florida in 2007. Median BRFSS response rate during 2006-2010 was 52.3%.
From 2006 to 2010, age-adjusted CHD prevalence in the United States declined overall from 6.7% to 6.0%. Similar declines were observed across age group, sex, and education categories. Among racial/ethnic populations, declines from 2006 to 2010 were observed among whites (6.4% to 5.8%) and Hispanics (6.9% to 6.1%).
In 2010, the prevalence of CHD was greatest among persons aged ≥ 65 years (19.8%), followed by those aged 45-64 years (7.1%) and those aged 18-44 years (1.2%). CHD prevalence was greater among men (7.8%) than women (4.6%), and among those with less than a high school education (9.2%), compared with high school graduates (6.7%), those with some college (6.2%), and those with more than a college degree (4.6%). Among racial/ethnic populations, CHD prevalence was greatest among American Indians/Alaska Natives (11.6%), followed by blacks (6.5%), Hispanics (6.1%), whites (5.8%), and Asians or Native Hawaiians/Other Pacific Islanders (3.9%). By race and sex in 2010, the greatest male prevalences were among American Indian/Alaska Natives (14.3%) and whites (7.7%), and the greatest females prevalences were among American Indian/Alaska Natives (8.4%) and blacks (5.9%).
By state, from 2006 to 2010, the greatest statistically significant linear declines in age-adjusted CHD prevalence were 23.1% in West Virginia (from 10.4% to 8.0%) and 22.1% in Missouri (from 7.7% to 6.0%). Although five states showed an increase in CHD prevalence from 2006 to 2010, none of the five showed a statistically significant linear increase. In 2010, CHD prevalence ranged from 3.7% in Hawaii and 3.8% in DC to 8.0% in West Virginia and 8.2% in Kentucky, with the greatest regional prevalences generally observed in the South (Figure).
Jing Fang, MD, Kate M. Shaw, MS, Nora L. Keenan, PhD, Div for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion. Corresponding contributor: Jing Fang, firstname.lastname@example.org, 770-488-5142.
During the past half century, the CHD mortality rate has declined continuously1; a Healthy People 2020 objective is to lower the death rate 20%, from a baseline of 126.0 per 100,000 population in 2007 to 100.8. The decline in the mortality rate suggests that more persons are living with CHD, which should result in an increase in the prevalence of CHD, not a decrease as described in this report. However, the decline in prevalence in this report was affected not only by CHD mortality but also by CHD incidence, which is decreased by the prevention and control of CHD risk factors. Given that CHD mortality is declining, the observed decline in prevalence of CHD in this study suggests that CHD incidence also has declined. Although no national-level surveillance of CHD incidence is conducted in the United States, a decline in CHD incidence from 1980 to 1992 was observed in a population-based study.5 Additionally, a 2007 report attributed 47% of the decline in CHD mortality to improvements in treatment and 44% to a reduction in risk factors.6 Because improvements in treatment would tend to increase CHD prevalence, the decline in prevalence is consistent with the reported decline in the prevalence of a population at high risk (i.e., persons with uncontrolled hypertension, uncontrolled high levels of low-density lipoprotein cholesterol, and current smokers), as noted in the recent report on the U.S. Department of Health and Human Services Million Hearts initiative.7
This report estimates a national CHD prevalence of 6.0%. In 2007, CDC estimated the national prevalence of CHD at 6.5%, based on data from the 2005 BRFSS survey.8 Since 2005, the prevalence of self-reported CHD has shown a significant decline. In the only other recent report estimating CHD prevalence, data from the 2005-2008 National Health and Nutrition Examination Survey were used to calculate an estimate of 7.0%, slightly greater than the BRFSS estimates but including a slightly older population: U.S. adults aged ≥ 20 years.9
This report is subject to at least six limitations. First, BRFSS is a telephone survey that excludes persons living in institutions, nursing homes, long-term care facilities, and correctional institutions, and results might not be applicable to these populations. Second, the 52.3% median response rate might further limit generalizability of the findings, if the sociodemographics of nonrespondents differed from respondents. Third, these BRFSS surveys included only persons with landline telephones. The increasing number of households with cellular telephones only might make BRFSS increasingly less representative of the general U.S. adult population. Fourth, BRFSS is conducted in English and Spanish and excludes persons who cannot speak either one of those languages. Fifth, BRFSS data are self-reported and subject to recall bias and social desirability effects. However, should bias exist, no evidence suggests that it would confound trend estimates by fluctuating from year to year. Finally, no data were collected regarding CHD incidence, which might have shown its effect on the finding for CHD prevalence.
The CDC National Heart Disease and Stroke Prevention Program funds 41 states and DC, with a focus on developing and sustaining population-based strategies that target an identified area of a state or segment of the population.10 The goal of the program is to increase state capacity to address the issues related to control and prevention of heart disease, stroke, and related risk factors (e.g., hypertension and high levels of low-density lipoprotein cholesterol). Examples of preventive interventions include the enhancement of clinical-based management of treatment for hypertension and high cholesterol and the promotion of patient use of home blood pressure monitoring. The data from this report can help health planners develop more targeted prevention programs for states and populations with greater CHD prevalence (e.g., American Indian/Alaska Native men and black women). Development of effective prevention programs targeting populations with greater CHD prevalence should reduce risk factors and CHD incidence, which will continue the decline in both CHD prevalence and CHD deaths.
The 2005 Behavioral Risk Factor Surveillance System survey found a prevalence of coronary heart disease (CHD) in the United States of 6.5% among adults aged ≥ 18 years and certain disparities in prevalence by sex, race, education, and state of residence.
What is added by this report?
From 2006 to 2010, CHD prevalence overall in the United States decreased from 6.7% to 6.0%. Prevalence varied substantially by sex (men, 7.8%, versus women, 4.6%), race (American Indians/Alaska Natives, 11.6%, versus Asians or Native Hawaiians/Other Pacific Islanders, 3.9%), education (those with less than a high school education, 9.2%, versus those with more than a college degree, 4.6%), and state of residence, with prevalence generally greater in the South, the highest in Kentucky (8.2%) and the lowest in Hawaii (3.7%).
What are the implications for public health practice?
Prevention programs can be targeted at the states and populations with the greatest prevalence of CHD to meet the Healthy People 2020 objective of reducing the U.S. CHD death rate by 20%.
*All respondents categorized by race were non-Hispanic. Hispanic respondents might be of any race.
Prevalence of Coronary Heart Disease —United States, 2006-2010. JAMA. 2011;306(19):2084–2086. doi:
Create a personal account or sign in to: